CSF1R (colony stimulating factor 1 receptor): Medicines That Act On It

Medicines acting on CSF1R

most-trialled first

Medicine	How it acts	Source	Current trials here
Sunitinib CHEMBL535	Macrophage colony stimulating factor receptor inhibitor Inhibitor Small molecule	ChEMBL only	21
Pazopanib CHEMBL477772	Macrophage colony stimulating factor receptor inhibitor Inhibitor Small molecule	✓ Both	10
Axatilimab CHEMBL4594608	Macrophage colony stimulating factor receptor inhibitor Inhibitor Antibody	✓ Both	8
Quizartinib CHEMBL576982	Macrophage colony stimulating factor receptor inhibitor Inhibitor Small molecule	✓ Both	7
Sunitinib Malate CHEMBL1567	Macrophage colony stimulating factor receptor inhibitor Inhibitor Small molecule	ChEMBL only	3
Emactuzumab CHEMBL3545370	Macrophage colony stimulating factor receptor inhibitor Inhibitor Antibody	✓ Both	2
Seralutinib CHEMBL4650333	Macrophage colony stimulating factor receptor inhibitor Inhibitor Small molecule	ChEMBL only	2

“Both” means ChEMBL and the Guide to Pharmacology each record this medicine acting on this protein; “only” means one source records it and the other does not (often because it lists fewer secondary targets). The Guide to Pharmacology adds a medicine here only when this protein is its primary target. Medicines without a link have no page on this site yet.

Diseases these medicines are tested for

by number of CSF1R medicines

Disease	Medicines tested	Furthest trial phase
Acute myeloid leukemia	4	Phase 3
Breast cancer	3	Phase 3
Non-small cell lung carcinoma	3	Phase 3
Age-related macular degeneration	3	Phase 2
Fallopian tube cancer	2	Phase 3
Hepatocellular carcinoma	2	Phase 3
Kidney cancer	2	Phase 3
Ovarian carcinoma	2	Phase 3
Primary peritoneal carcinoma	2	Phase 3
Soft tissue sarcoma	2	Phase 3
Myelodysplastic syndrome	2	Phase 2/3
Acute lymphoblastic leukemia	2	Phase 2
Adenoid cystic carcinoma	2	Phase 2
Bladder transitional cell carcinoma	2	Phase 2
Chronic myelomonocytic leukemia	2	Phase 2

From ChEMBL's drug-disease records, which draw on trial registries. A trial phase is not an approval; approved uses are on each medicine's page from the regulators' own records.

How this page is built

Which medicines act on this protein comes from two independent, expert-curated sources: ChEMBL's mechanism-of-action records (via the Open Targets Platform) and the IUPHAR/BPS Guide to PHARMACOLOGY. Each row says which of them lists it. Data from them is shared here under their share-alike licences (CC BY-SA 3.0 and 4.0).

Open Targets Platform, target ENSG00000182578 ↗ target record, CC0 1.0
ChEMBL mechanism of action and drug indication data ↗ curated by EMBL-EBI, CC BY-SA 3.0
IUPHAR/BPS Guide to PHARMACOLOGY 2026.3 ↗ expert-curated ligand-target interactions; database ODbL, contents CC BY-SA 4.0

A job re-reads both sources every 30 days. Medicines are matched to our pages by exact name or a ChEMBL-curated synonym, and to the Guide to Pharmacology by ChEMBL ID or exact name, never by a close spelling. No AI drafting. See our methodology. The Open Targets data on this page was last retrieved on 30 Sep 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.